On September 2, 2026, the domestically developed 'Dishi Lingfeng' microsurgical robot, created by Hangzhou Dessight Biomedical Co. Ltd., successfully completed its first patient enrollment in a registered clinical trial for robotic-assisted lymphaticovenular anastomosis (LVA) at Zhejiang Provincial People's Hospital. Led by Professor Zheng Youmao, the procedure marked China's first registered clinical trial using a surgical robot for super-microsurgery to treat secondary lymphedema. The Dishi Lingfeng system overcomes the limitations of human dexterity with real-time tremor filtering, motion scaling, and micro-wristed instruments capable of micron-level precision, enabling the connection of lymphatic vessels as small as 0.1 to 1 millimeter in diameter. This multi-center trial will generate rigorous clinical evidence to support regulatory approval and demonstrate the safety and effectiveness of robotic-assisted super-microsurgery for lymphedema patients.

AIPher, an AI-native drug discovery company, has completed an angel financing round worth hundreds of millions of yuan, led by Xianghe Capital, with participation from LINKX CAPITAL and a well-known industrial fund. The funds will support R&D of its drug foundation models, including DrugCLIP, and PharmAgents, an AI agent engine for drug discovery. Capital will also be used to build a multimodal closed-loop system integrating computational and experimental “dry” and “wet” labs and advance proprietary and partnered drug pipelines. Its leading pipeline has reached the Pre-PCC stage. AIPher’s core technology originates from teams led by Professor Lan Yanyan and Academician Zhang Yaqin at Tsinghua University’s Institute for AI Industry Research. The company aims to use AI to transform drug discovery from tool optimization to full-process decision-making, addressing long development cycles, high costs, and low success rates. No financial advisor was disclosed.

On August 31, ProteLight Pharmaceuticals filed an 18A prospectus with the HKEX. Two months earlier, its Class 1 drug Puyike (peceleganan spray) gained NMPA approval as the world's first first-in-class (FIC) -ganan anti-infective for secondary burn-wound infections. Despite antimicrobial peptides being a promising answer to drug resistance, the FDA has approved only five such drugs in nearly 25 years, and China only seven. Six funding rounds have raised about RMB 790 million at a post-money valuation of RMB 2.5 billion, with the PICC Sci-Tech Innovation Fund among investors. Founder Chen Yuxin, PhD, a two-decade veteran, built Puyike on his membrane discrimination theory: it selectively attacks bacterial membranes and remains effective even against partially mutated pathogens.

GensKey’s self-developed mNGS kit has received a Class III medical device registration certificate from China’s National Medical Products Administration (NMPA), marking China’s first Class III registration for pathogen metagenomic testing and the first mNGS infectious pathogen diagnostic kit approved by a national regulator worldwide. The U.S. FDA has yet to approve any mNGS diagnostic kit, while the EU has not completed approval of any broad-spectrum infectious pathogen mNGS sequencing kit. China’s lead reflects strong clinical demand and rapid technological iteration. With mNGS and tNGS still at low penetration but high growth, clinical needs are accelerating standardization, regulatory approval and reimbursement. As a key tool for severe and complex infections, mNGS has historically relied on centralized laboratories with limited standardization. The new Class III approval could reshape the market and unlock a billion-yuan incremental opportunity.

Inspired by Avatar, Tianjin University graduate Zhang Xingzhi became convinced that brain-computer interfaces (BCI) would reach an industrialization tipping point. Over a decade, he progressed from human-computer interaction research to an executive role at a listed company. In 2025, amid policy and technological breakthroughs, he resigned to found WABO Technology. The company completed three financing rounds within three months. Rather than focusing on medical applications, WABO Technology centers on the “Human Neural Intent Model,” integrating proprietary hardware with software to collect neural signals and build a large EEG model. Zhang believes BCI will have a “GPT moment,” driven by massive real-world neural data. By end-2025, he had built a core team in Chengdu and adopted a lightweight, AI-native model.

This industry news roundup highlights three major pharmaceutical developments: 1) AbbVie's investigational bispecific antibody etentamig achieved positive topline results in the Phase 3 CERVINO trial, meeting dual primary endpoints for relapsed/refractory multiple myeloma; 2) Gan & Lee Pharmaceuticals and Menarini Group reached an exclusive licensing agreement for the long-acting GLP-1 therapy bofanglutide, with a total potential deal value of up to €726 million; and 3) HUTCHMED entered an exclusive licensing agreement with a GSK subsidiary for the KRAS-EGFR antibody-targeted conjugate HMPL-A830, with a total potential deal value of up to $1.295 billion.

Medtronic has announced a strategic investment of approximately $700 million in Chinese surgical-robotics startup Cornerstone Robotics (Kangnuositeng) and secured distribution rights for its Sentire laparoscopic surgical robot in markets outside the U.S. In oncology news, Akeso reported that an interim analysis of overall survival (OS) in its Phase III HARMONi-2 study met the key secondary endpoint with statistical significance. The trial evaluates Akeso's PD-1/VEGF bispecific antibody ivonescimab against pembrolizumab as a first-line treatment for PD-L1-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC).

ApicHope Pharmaceutical Group Co., Ltd. announced that its innovative drug AR882 has successfully met the primary endpoint in a Phase III clinical trial for treating gout with hyperuricemia. This significant milestone positions AR882 as a potential breakthrough therapy for millions of patients facing limited treatment options. The company plans to leverage these positive results to advance discussions with China's National Medical Products Administration for potential marketing authorization.

Betta Pharmaceuticals has received approval from China's NMPA for ensartinib hydrochloride capsules as a post-surgical adjuvant treatment for ALK-positive Stage IB to IIIB non-small cell lung cancer (NSCLC), marking the drug's third approved indication. Clinical data demonstrated a two-year disease-free survival rate of 86.4% and an 80% reduction in disease recurrence risk compared to the control group. This approval expands treatment options for early-stage ALK-positive NSCLC patients, a subtype that accounts for 3% to 5% of all NSCLC cases and predominantly affects younger patients with less smoking history.

The interim analysis of the HARMONi-2 trial revealed that Akeso's ivonescimab demonstrated superior overall survival compared to pembrolizumab (Keytruda) in first-line PD-L1-positive non-small cell lung cancer. By outperforming the world's top-selling cancer therapy on the most rigorous clinical endpoint, ivonescimab cements the cornerstone status of IO 2.0 bispecific antibodies, transitioning the narrative from 'me-too' substitution to undeniable superiority. This landmark clinical victory has catalyzed a rally in the biotech sector and marks a pivotal shift from theme-based trading to data-driven valuation, prompting investors to fundamentally reassess and upgrade the clinical and commercial value of Chinese innovative drugs on the global stage.

Amid slowing internet healthcare traffic and the limits of single-transaction models, Fangzhou Pharmaceutical is repositioning itself as a “lifelong health service partner.” In H1 2026, revenue reached RMB 1.8245 billion, up 22.2% YoY, while monthly active users exceeded 14.7 million, validating the new strategy. As online consultations struggle to generate long-term value and pharmaceutical e-commerce faces margin pressure from price competition, chronic disease management offers a promising growth path due to high user stickiness, strong demand, and willingness to pay. Focusing on “AI + chronic disease services,” Fangzhou has built an integrated system covering consultation, medication guidance, health interventions, follow-ups, and data monitoring, creating service premiums and increasing user lifetime value. The model provides a potential path for internet healthcare platforms to overcome growth bottlenecks and unlock long-term user value.

BCIs have long faced neural decoding latency, limiting patients’ sense of “embodiment” and prosthetic integration. Recently, the Shanghai Institute of Microsystem and Information Technology of the Chinese Academy of Sciences and QBOSON achieved microsecond-level neural decoding on a 1,000-qubit quantum computer, offering a potential solution to computational bottlenecks. Following the breakthrough, China’s first BCI-specific fund, the “Heying Brain-Computer Interface Fund,” partnered with QBOSON. The two sides plan to leverage quantum computing to process massive noisy neural signals and accelerate deep-brain intention decoding via cloud computing. Within three to five years, they aim to achieve hardware-accelerated decoding for language and motor applications, potentially overcoming BCI latency and advancing the technology toward becoming an extension of the human body.

BD deals between US and European pharma are growing more complex and volatile, signaling new shifts across the innovative drug industry. "BD Deep Dive" focuses on how IIT clinical research is reshaping FDA approvals, capital markets, and cross-border collaboration models. Industry insiders said a US rare-disease company is preparing to partner with a Chinese drugmaker on an siRNA IIT study, using Chinese data to accelerate FDA approval and cut early-stage clinical costs. Beacon Capital's founder noted that many overseas companies frequently sought IIT resource connections in China over the past six months, covering small nucleic acids and gene therapy. Although the new Regulation No. 818 brings uncertainty, IIT cases unlocking M&A and capital-market value still attract global biotechs. Overseas companies hope to use China's vast patient pools and efficient clinical system as a "fast track" to the FDA, compressing time and capital costs.

Inspired by Avatar, Tianjin University graduate Zhang Xingzhi became convinced that brain-computer interfaces (BCI) would reach an industrialization tipping point. Over a decade, he progressed from human-computer interaction research to an executive role at a listed company. In 2025, amid policy and technological breakthroughs, he resigned to found WABO Technology. The company completed three financing rounds within three months. Rather than focusing on medical applications, WABO Technology centers on the “Human Neural Intent Model,” integrating proprietary hardware with software to collect neural signals and build a large EEG model. Zhang believes BCI will have a “GPT moment,” driven by massive real-world neural data. By end-2025, he had built a core team in Chengdu and adopted a lightweight, AI-native model.

In collaboration with Central South University, Tencent's AI for Life Sciences laboratory has built a new AI framework, UniPert-G2CP, with its paper accepted by Cell. The model integrates multimodal molecular perturbation factor representations, enabling transfer learning from genetic to chemical perturbation phenotypes, connecting genetic and chemical screening for more accurate perturbation prediction, mechanism discovery, and efficient computer-assisted drug screening. Its breakthrough: answering why the same compound responds differently across genetic and cellular contexts. Previous AI achievements in drug development shared a blind spot — ignoring downstream effects after compounds enter real cells, making results irreproducible and costly for pharma. UniPert-G2CP, a two-stage deep learning framework, predicts phenotypic responses to compounds in specific cellular contexts from gene-level perturbation information, offering a solution to this dilemma.

Over the past six months, more than $8 billion has flowed into the oral cyclic peptide sector through financing and BD deals, as Big Pharma and leading investors compete for platforms and pipelines. Recent FDA approvals of MSD’s Enlicitide and J&J’s Icotrokinra have validated the modality, but most assets remain preclinical or in early clinical development, with low oral bioavailability still a key technical hurdle. AI-driven platforms from Unnatural Products, Syneron Bio, and Pinnacle Medicines are attracting substantial capital, signaling a shift toward platform capabilities that can iteratively address these challenges. While validated extracellular targets offer near-term commercial certainty, the greater long-term potential lies in drugging intracellular targets inaccessible to small molecules or antibodies. Given the high scientific and development risks, platform resilience and a staged target strategy will be critical to success.

On August 25, Shanghai Pharmaceuticals announced its subsidiary SPH Holding will publicly list for transfer a 51% stake in Shanghai Shangyao Xinte Dongan Pharmacy at a minimum price of RMB 178.5 million, exiting control of the pharmacy upon completion. The move follows a year of intensive restructuring of retail pharmacy assets nationwide, as state-owned pharmaceutical platforms accelerate divestment of non-core assets. Founded in September 2023, the pharmacy has shown strong profitability in its three years: 2025 revenue of RMB 384 million, net profit of RMB 33.38 million, with continued profitability in January–May 2026. Despite an asset-liability ratio above 96%, the market approach — selected over the asset-based approach — appraised the 51% stake at about RMB 178.4 million, broadly matching the listing price.

SENVIV is building a digital twin foundation from 12 million hours of physiological time-series data. While current health AI can interpret text and provide recommendations, it lacks direct access to human physiological data, making the “biological human” the next frontier for AI. Continuous vital sign data is fundamentally different from internet-derived data: difficult to observe, collect, and structure, it is often described as “life’s dark matter.” SENVIV uses a non-contact, minimally intrusive sensing approach, combining smart rings during the day with non-contact devices at night to reduce device burden and support long-term adherence. After 12 years of continuous data collection, the company has accumulated a large-scale vital sign dataset, including 12 million hours of continuous physiological data, of which 3.6 million hours were collected in clinical settings.

In H1 2026, Neutech Group's elderly care technology and services business grew revenue 57.4% year over year, the group's fastest-growing segment — marking the shift of its smart elderly care services from Shenyang pilot exploration to nationwide scaled replication. China's 320 million-plus elderly population faces fragmented services, difficult supply-demand matching, and regulatory gaps, and traditional single-point systems have left information silos. As AI and big data mature and policy promotes the "15-minute eldercare service circle", a city-level "digital foundation" for elderly care spanning institutions, communities, and home-based care has become a key industry entry point. Neutech launched the "Shengqing Kangyang" platform in Shenyang in 2025; with a year of smooth operations, it provides a replicable digital solution to the silver-aging challenge, ushering the industry into a new cycle of high-quality development.

China’s innovative drug BD market is heating up in 2026, with the industry shifting from “valuation-driven” to “performance- and global commercialization-driven.” VCBeat launched the “Year of Realization: Dialogues on BD” interview series to explore the practices of pharmaceutical BD decision-makers. Xie Xin, Executive Director of Sino Biopharm, has participated in multiple landmark transactions, overseeing M&A and financing activities. In recent years, Sino Biopharm has made significant progress in BD, completing four out-licensing deals with MNCs, including high-value collaborations with Sanofi and AstraZeneca in 2026. On the acquisition side, it acquired LaNova Medicines in 2025 and Hygieia in early 2026. In the interview, Xie Xin addressed the “selling young crops” debate, emphasizing that in-house R&D capabilities remain the top priority for corporate BD, while BD itself is a discipline built on timing, judgment, and persistence.

Medtronic has announced a strategic investment of approximately $700 million in Chinese surgical-robotics startup Cornerstone Robotics (Kangnuositeng) and secured distribution rights for its Sentire laparoscopic surgical robot in markets outside the U.S. In oncology news, Akeso reported that an interim analysis of overall survival (OS) in its Phase III HARMONi-2 study met the key secondary endpoint with statistical significance. The trial evaluates Akeso's PD-1/VEGF bispecific antibody ivonescimab against pembrolizumab as a first-line treatment for PD-L1-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC).

Hansoh Pharmaceutical Group has submitted a China marketing application for risvutatug rezetecan (HS-20093), a fully human B7-H3 ADC with a topoisomerase inhibitor payload, for platinum-refractory small cell lung cancer (SCLC). The filing is supported by positive Phase III ARTEMIS-008 results announced in July 2026, which met its primary overall survival endpoint and significantly improved survival versus topotecan, with consistent progression-free survival benefits. Safety remained consistent with prior studies. This is the first positive Phase III result showing a B7-H3 ADC can significantly improve overall survival. In December 2023, Hansoh granted GSK exclusive rights to develop and commercialize the drug outside Greater China, where GSK is conducting Phase III trials. As SCLC accounts for about 15% of lung cancers and has limited second-line options, HS-20093 could address a significant unmet medical need.

In under six months, GE HealthCare has obtained regulatory clearance for its Photonova Spectra photon-counting CT system across the US, Japan, and Europe, marking a pivotal shift from Siemens Healthineers' years-long monopoly to a multi-player competitive landscape. GE's system employs a proprietary Deep Silicon detector technology, distinguishing it from the CZT-based approaches of Siemens and Chinese competitors. Meanwhile, Chinese manufacturers Neusoft Medical and United Imaging Healthcare have also advanced into PCCT commercialization with domestic regulatory approvals and initial deliveries in 2025-2026, narrowing the generational technology gap to historic lows. The article argues that the next phase of PCCT competition will hinge not on who can build the equipment, but on who can demonstrate tangible clinical value, define clear diagnostic use cases, and deliver measurable returns to hospitals investing tens of millions in next-generation imaging systems.

On September 1, 2026, Medtronic announced a strategic partnership with Chinese surgical robotics company Cornerstone Robotics, investing approximately $700 million for distribution rights of the Sentire® robotic-assisted laparoscopic surgery system outside the U.S. The Sentire platform features fully in-house developed core technologies, including the world’s first 5mm wristed instruments, 8mm 4K 3D fluorescence imaging, and proprietary force-feedback and direct-drive control systems. This investment complements Medtronic’s existing Hugo™ system, creating a dual-platform strategy that addresses diverse surgical specialties and economic markets. With regulatory approvals already secured in China (NMPA), Europe (CE), and Singapore (HSA), the deal accelerates Medtronic’s global surgical robotics rollout amid intensifying competition and strategic pressure on its traditional surgical device business.

Dizal Pharmaceutical listed on Shanghai's STAR Market in 2021, raising about RMB 2.1 billion, and filed an H-share application with the Hong Kong Stock Exchange in August 2026, pursuing an A+H dual listing. Formerly AstraZeneca's early-stage drug discovery unit in Asia, it was spun off in 2017 with preclinical assets and funding from AstraZeneca, led by CEO Zhang Xiaolin, PhD. At its STAR listing, only two candidates were in late-stage development; in August 2023, Zegfrovy (sunvozertinib) became China's first innovative drug for EGFR exon 20 insertion-mutant NSCLC, lifting H1 2026 revenue to RMB 523 million. After filing its Hong Kong prospectus, Dizal signed a record-breaking license agreement with AstraZeneca effective August 31, securing a USD 600 million upfront (about RMB 4 billion) and other payments. The company is not yet overall profitable, with multiple pipelines awaiting clinical validation.

China's Center for Drug Evaluation (CDE) has signaled that YL202, an injectable HER3-targeted antibody-drug conjugate (ADC) developed by MediLink Therapeutics, is being considered for Breakthrough Therapy Designation for the treatment of previously treated, unresectable locally advanced, recurrent or metastatic melanoma. If approved, YL202 would become the first HER3 ADC to receive breakthrough therapy status in China. Currently in Phase III clinical development, YL202 is built on MediLink's proprietary TMALIN platform. The potential designation underscores the significant unmet medical need in advanced melanoma and highlights the growing competitiveness of Chinese biotech in the rapidly expanding ADC space, where no HER3 ADC has been approved globally to date. MediLink has also secured a major licensing deal with BioNTech worth up to $1 billion, reflecting strong global interest in Chinese-developed oncology therapies.

Changzhou Pharmaceutical Factory Co., Ltd., a subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH), has obtained approval from China's National Medical Products Administration (NMPA) to manufacture ruxolitinib phosphate tablets under three drug registration certificates. The approved indications cover the treatment of myelofibrosis and graft-versus-host disease (GVHD), expanding treatment options for Chinese patients with rare blood disorders. Ruxolitinib, originally co-developed by Incyte Corporation and Novartis AG, was first approved by the U.S. FDA in 2011. This domestic production approval marks a significant milestone for SPH, strengthening its portfolio of specialized therapies for rare diseases and improving patient access to effective treatments for complex hematologic conditions.

On August 28, 2026, DualityBio entered a global collaboration with Genentech, a Roche Group company, to develop next-generation ADCs using its DUPAC™ platform. DualityBio received $45 million upfront and is eligible for over $1 billion in milestone payments. DualityBio will lead discovery and early clinical development, while Genentech will hold exclusive global licensing rights and oversee later development and commercialization. The deal highlights the rising global competitiveness of Chinese ADC innovation. As ADC technology enters a new phase of iteration, tumor resistance remains a key challenge. DUPAC™ is DualityBio’s next-generation payload platform designed to address such limitations, with ADCs based on DUP5 and DUP9 showing robust preclinical results.

In mid-June, Novo Nordisk’s global management visited China to integrate Chinese R&D expertise into its global strategy. China is emerging as a global innovation “accelerator,” combining scientific strength with cost efficiency. Novo Nordisk is expanding collaboration from early research to preclinical candidate development, incorporating Chinese innovations into its global pipeline. From January to June 2026, China’s outbound innovative-drug licensing deals hit a record high, with Chinese pharma companies accounting for eight of the top 10 global deals. MNC transactions by Eli Lilly and AstraZeneca focused on early-stage assets. McKinsey data show China’s biopharma discovery and development timelines are shorter than the global average, highlighting a structural efficiency advantage. China now accounts for about 30% of global drug candidates in development, while clinical trials surpassed 5,000.

InnoCare Pharma secured CDE approval to launch a registrational Phase III trial of its BCL-2 inhibitor mesutoclax in AML, setting up a head-to-head challenge against AbbVie’s venetoclax. China’s health insurance instant settlement now covers over 90% of designated medical institutions, while the new DRG/DIP 3.0 payment scheme promotes “same disease, same payment” at grassroots facilities. Biokin’s BL-B01D1 met its primary endpoint in a Phase III lung cancer trial, Harbour BioMed’s HBM7004 received IND approval in China, and AstraZeneca launched tezepelumab for severe asthma. EyePoint’s faricimab implant failed its Phase III trial, triggering a sharp drop in Betta Pharmaceuticals’ shares. Meanwhile, Enhertu demonstrated superior first-line efficacy in lung cancer, Chugai licensed a dengue antibody to GSK, Macau announced free community healthcare under its new Five-Year Plan, and YimuFeng filed for a Hong Kong IPO to advance its solid tumor CAR-T therapy.